ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
Public ClinicalTrials.gov record NCT00834080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-Label Study of the Safety and Tolerability of VIVITROL Administered to Health Care Professionals Participating in an Extended Outpatient Treatment Program for Opioid Dependence
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and tolerability of Medisorb® naltrexone (VIVITROL®) when administered over a period of 24 months to health care professionals who have a history of opioid dependence.
Study identification
- NCT ID
- NCT00834080
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- Apr 30, 2012
- Completion
- Apr 30, 2012
- Last update posted
- Dec 10, 2018
2009 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Clinical Study Site | Colton | California | 92324 | — |
| Alkermes Clinical Study Site | Oceanside | California | 92056 | — |
| Alkermes Clinical Study Site | Lauderhill | Florida | 33319 | — |
| Alkermes Clinical Study Site | Hoffman Estates | Illinois | 60194 | — |
| Alkermes Clinical Study Site | St Louis | Missouri | 63109 | — |
| Alkermes Clinical Study Site | Elmsford | New York | 10523 | — |
| Alkermes Clinical Study Site | Canton | Ohio | 44718 | — |
| Alkermes Clinical Study Site | Philadelphia | Pennsylvania | 19118 | — |
| Alkermes Clinical Study Site | Philadelphia | Pennsylvania | 19125 | — |
| Alkermes Clinical Study Site | Austin | Texas | 78754 | — |
| Alkermes Clinical Study Site | Dallas | Texas | 75225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00834080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2018 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00834080 live on ClinicalTrials.gov.